US EditionPublished • loading... • Updated
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying ...
Summary by Hastings Tribune
2 Articles
2 Articles
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB
FRIENDSWOOD, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today...
·Manila, Philippines (the)
Read Full Article
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying ...
FRIENDSWOOD, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data evaluating DecisionDx-Melanoma’s i31-SLNB test result for prediction of sentinel lymph node…
·Nebraska, United States
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left0Leaning Right1Center1Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
